Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Revenue (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Revenue for 16 consecutive years, with $164.9 million as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 4.89% year-over-year to $164.9 million; the TTM value through Mar 2026 reached $769.1 million, up 12.2%, while the annual FY2025 figure was $761.4 million, 12.79% up from the prior year.
  • Revenue hit $164.9 million in Q1 2026 for Corcept Therapeutics, down from $202.1 million in the prior quarter.
  • Across five years, Revenue topped out at $207.6 million in Q3 2025 and bottomed at $93.7 million in Q1 2022.
  • Average Revenue over 5 years is $146.2 million, with a median of $146.8 million recorded in 2024.
  • Year-over-year, Revenue grew 4.28% in 2022 and then surged 47.69% in 2024.
  • Corcept Therapeutics' Revenue stood at $103.1 million in 2022, then soared by 31.39% to $135.4 million in 2023, then surged by 34.33% to $181.9 million in 2024, then increased by 11.12% to $202.1 million in 2025, then decreased by 18.42% to $164.9 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $164.9 million, $202.1 million, and $207.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.